Blog Articles
A scientific hub to keep you informed about our latest research and company updates.
Your compound has shown efficacy in a preclinical disease model – now what? Moving from exploratory studies to GLP toxicology studies
Plasma NfL, p-tau217, or Aβ42/40: Which Alzheimer’s disease biomarkers should you include in your preclinical efficacy study?
Transgenic Amyloid, Tau, Seeding, or combined Amyloid/Tau pathology mouse models — which is the right one for your drug development program?
Morris Water Maze, Rotarod and beyond: How do you build a comprehensive behavioral test battery when outsourcing your preclinical Alzheimer’s disease efficacy study?
Accelerating Angelman Syndrome Research: InnoSer now offers Angelman Syndrome Mouse Model
![InnoSer Presents New Data on Tau[P301S] and α-Synuclein Combination Models for Neurodegenerative Research at ADPD 2025](https://www.innoserlaboratories.com/wp-content/uploads/2025/03/ADPD-2025-InnoSer-Neurodegenerative-Disease-Models-400x250.png)
InnoSer Presents New Data on Tau[P301S] and α-Synuclein Combination Models for Neurodegenerative Research at ADPD 2025
Top 4 Multi-Organ-on-a-Chip TissUse Assays and Why You Should Include them in Your Preclinical Research in 2025
How to Advance your Preclinical Research Using Mouse Data to Establish PK/PD Relationships
Exploring InnoSer’s Key In vitro Oncology Services: PD-1 PD-L1 Blockade Assay
Introduction to InnoSer’s Preclinical Epilepsy Research CRO Platform
The Application of Bioluminescence Imaging in Preclinical Oncology Research and Beyond
info@innoserlaboratories.com